Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 18/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963877 | 0.87 | F2 (0.47) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7404140 | 0.81 | F2 (0.50) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7408227 | 0.79 | F2 (0.46) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7409009 | 0.78 | F2 (0.43) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL7408144 | 0.78 | F2 (0.51) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7449943 | 0.78 | F2 (0.53) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6986633 | 0.77 | ALDH1A1 (0.42) | F2PRSS1PRSS2PRSS3KDM4E | |
| SCHEMBL5855071 | 0.73 | F2 (0.68) | F2PRSS1 | |
| SCHEMBL7409413 | 0.73 | CNR1 (0.39) | F2PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL7447096 | 0.72 | ROCK2 (0.37) | KDM4ELMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103379-A1 | Process for making a thrombin inhibitor | MERCK SHARP & DOHME LTD. (GB) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103379-A1 | Process for making a thrombin inhibitor | TFPI, TFPI2, F2 | F2 3/4885PRSS1 175/4885PRSS2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.